Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

Item Type:	Letter
Title:	Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer
Creators Name:	Gupta, S. and Strohbehn, I.A. and Wang, Q. and Hanna, P.E. and Seethapathy, R. and Prosek, J.M. and Herrmann, S.M. and Abudayyeh, A. and Malik, A.B. and Loew, S. and Carlos, C.A. and Chang, W.T. and Beckerman, P. and Mithani, Z. and Shah, C.V. and Renaghan, A. and de Seigneux, S. and Campedel, L. and Kitchlu, A. and Shin, D.S. and Coppock, G. and Lumlertgul, N. and Garcia, P. and Ortiz-Melo, D.I. and Rashidi, A. and Sprangers, B. and Aggarwal, V. and Benesova, K. and Jhaveri, K.D. and Cortazar, F.B. and Weins, A. and Zuo, Y. and Mooradian, M.J. and Reynolds, K.L. and Leaf, D.E. and Sise, M.E.
Keywords:	Acute Kidney Injury, Antineoplastic Combined Chemotherapy Protocols, Humanized Monoclonal Antibodies, Lung Neoplasms
Source:	Kidney International
ISSN:	0085-2538
Publisher:	Nature Publishing Group
Volume:	102
Number:	4
Page Range:	930-935
Date:	October 2022
Additional Information:	Kai Schmidt-Ott is a member of the ICPi-AKI Consortium
Official Publication:	https://doi.org/10.1016/j.kint.2022.07.019
External Fulltext:	View full text on PubMed Central
PubMed:	View item in PubMed

Repository Staff Only: item control page